Shire has agreed an exclusive worldwide licensing deal to develop and commercialise a promising new autoimmune disease programme from AB Biosciences.
The agreement will see Shire take forward AB Biosciences' pan receptor interacting molecule (PRIM) programme, which leverages proprietary oligomeric Fc technology to underpin the creation of new therapies for autoimmune diseases and other immune-mediated disorders.
“Shire has licensed an AB Biosciences drug development programme for the potential treatment of autoimmune diseases.“
PRIM is a recombinant immunoglobulin product candidate that has shown encouraging preclinical data, including enhanced biological activity relative to currently approved intravenous immunoglobulin therapies, in preclinical models of autoimmune and inflammatory diseases.
Under the terms of the deal, AB Biosciences will grant Shire an exclusive, worldwide licence to its intellectual property relating to PRIM, in exchange for an upfront licence fee and milestone-based research, development and commercialisation payments.
Dr Andreas Busch, head of research and development and chief scientific officer at Shire, said: "AB Biosciences has demonstrated innovation in the area of antibody technology and protein design, and Shire is pleased to continue to advance this programme."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical